<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04175067</url>
  </required_header>
  <id_info>
    <org_study_id>09/08/2018-13-9</org_study_id>
    <nct_id>NCT04175067</nct_id>
  </id_info>
  <brief_title>Evaluation of Thiol Disulfide Balance in Stage 1 Endometrium Cancer</brief_title>
  <official_title>Assessment of Thiol Disulfide Balance in Early Stage Endometrium Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Muğla Sıtkı Koçman University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Muğla Sıtkı Koçman University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate thiol‑disulfide balance in early stage
      endometrium cancer patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date various oxidative stress paramaters were studied in patients with endometrial cancer,
      however dynamic thiol disulfide hemostasis has not been previously investigated.

      The thiol-disulfide balance in the circulation will be measured by the automated system
      created by Erel &amp; Neselioglu(1).

      References

      1- Erel O, Neselioglu S. A novel and automated assay for thiol/disulphide homeostasis. Clin
      Biochem 2014;47:326-32. doi:10.1016/j.clinbiochem.2014.09.026.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Actual">November 15, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum native thiol level</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>serum native thiol level in μmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum disulphide level</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>serum disulphide level in μmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>serum total thiol level</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>serum total thiol level in μmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the disulphide/native thiol ratio</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>the disulphide/native thiol ratio X (100 )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>disulphide/total thiol ratio</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>disulphide/total thiol ratio X (100 )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>native thiol/total thiol ratio</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>native thiol/total thiol ratio X (100 )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>total antioxidant capacity (TAC)</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>TAC in mmol trolox equivalent/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total oxidant capacity (TOC)</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>TOC in mmol H2O2 equivalent/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress index (OSI)</measure>
    <time_frame>preoperative in the morning or preprandial for healthy volunteers</time_frame>
    <description>OSI in mmol trolox/L.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">117</enrollment>
  <condition>Endometrium Cancer</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Endometrium cancer</arm_group_label>
    <description>stage I endometrium cancer n=57</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
    <description>Healthy volunteers n=60</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Disulphide(μmol/L)</intervention_name>
    <description>Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry</description>
    <arm_group_label>Endometrium cancer</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Native thiol (μmol/L)</other_name>
    <other_name>Total thiol (μmol/L)</other_name>
    <other_name>Nativethiol/totalthiol(%)</other_name>
    <other_name>Disulfide/nativethiol(%)</other_name>
    <other_name>Disulfide/totalthiol(%)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Total Oxidant Capacity(μmolH2O2Equiv/L)</intervention_name>
    <description>Aforementioned oxidative stress markers will be measured via Cobas c501(Roche Diagnostics, Indianapolis, IN, USA) used with sphectrophotometry</description>
    <arm_group_label>Endometrium cancer</arm_group_label>
    <arm_group_label>Healthy controls</arm_group_label>
    <other_name>Total Antioxidant Capacity(mmolTroloxEquiv/L)</other_name>
    <other_name>Oxidative stress Index (Arbitrary Unite)</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum blood samples for aech participant
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The preoperative diagnosis of Endometrium cancer was made histopathologically by
        endometrial biopsy. An experienced pathologist performed frozen section analysis according
        to the surgical staging scheme of the International Federation of Gynaecology and
        Obstetrics.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Histopathologically confirmed diagnosis of stage I endometrium cancer

        Exclusion Criteria:

          -  pulmonary disease

          -  pulmonary hypertension

          -  cardiac dysfunction

          -  renal dysfunction

          -  liver disease

          -  chronic ishemia

          -  systemic inflammation

          -  concomitant malignancy

          -  patients who use vitamin A,C or E (antioxidant vitamins)

          -  patients who use smoke

          -  patients who use drink alcohol

          -  patients who use addictive for any drug
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>endometrium cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Burak Sezgin</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mugla Sıtkı Kocman University Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mugla Sıtkı Kocman University Faculty of Medicine</name>
      <address>
        <city>Mugla</city>
        <zip>48000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 18, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>November 20, 2019</last_update_submitted>
  <last_update_submitted_qc>November 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Muğla Sıtkı Koçman University</investigator_affiliation>
    <investigator_full_name>Burak Sezgin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Early stage</keyword>
  <keyword>thiol disulfide hemostasis</keyword>
  <keyword>malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

